• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Lung Cancer: Targets and Therapy >Response to rapamycin analogs but not PD-1 inhibitors in PTEN-mutated metastatic non-small-cell lung cancer with high tumor mutational burden
【24h】

Response to rapamycin analogs but not PD-1 inhibitors in PTEN-mutated metastatic non-small-cell lung cancer with high tumor mutational burden

机译：对具有高肿瘤突变负担的PTEN突变的转移性非小细胞肺癌对雷帕霉素类似物而非PD-1抑制剂的反应

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In non-small-cell lung cancer (NSCLC) refractory to standard therapy and which lacks well-known oncogenic drivers, genomic profiling can still identify genomic alterations that may suggest potential sensitivity to targeted therapy. PTEN mutation in NSCLC may be sensitizing to analogs of rapamycin such as everolimus or temsirolimus, but more investigation is needed. We report the case of a patient with metastatic NSCLC harboring a PTEN mutation as well as high tumor mutational burden and PD-L1 positivity with a durable response to temsirolimus, but refractory to a checkpoint inhibitor. Even in the event of failure of treatment with checkpoint inhibitors in the background of a case with a higher tumor mutational burden and PD-L1 positivity, targeting specific genomic alterations may still result in patient benefit.
机译：在标准疗法难治且缺乏众所周知的致癌驱动因素的非小细胞肺癌（NSCLC）中，基因组图谱分析仍可以鉴定出可能暗示对靶向疗法敏感的基因组改变。 NSCLC中的PTEN突变可能对雷帕霉素类似物（如依维莫司或替西罗莫司）敏感，但还需要更多研究。我们报道一例转移性NSCLC患者，该患者具有PTEN突变以及高肿瘤突变负担和PD-L1阳性，对替西罗莫司有持久反应，但对检查点抑制剂无效。即使在具有更高的肿瘤突变负担和PD-L1阳性病例的情况下，使用检查点抑制剂治疗失败的情况下，靶向特定基因组改变仍可能使患者受益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号